实现生物基PHA材料全产业链闭环！麦得发生物完成B轮融资！

Core Viewpoint - Zhuhai Maidefa Biotechnology Co., Ltd. has completed a Series B financing round, primarily aimed at the research and production of PHA (polyhydroxyalkanoates) and global market expansion [1][2]. Group 1: Company Overview - Maidefa was established in 2019, focusing on the research, development, production, and commercialization of the next generation of fully biodegradable materials, specifically PHA and high-value health small molecules [2]. - The company has developed a complete industrial chain from upstream strain engineering to downstream product application, achieving open, continuous fermentation production and large-scale manufacturing of PHA [2][4]. Group 2: Product Features and Applications - The newly developed PHA bio-materials possess excellent thermoplastic processability, mechanical properties, biodegradability, biocompatibility, and high barrier characteristics, applicable in diverse fields such as food packaging, electronic packaging, 3D printing, drug release carriers, absorbable medical devices, and new food materials [4]. - Medical-grade PHA has successfully broken foreign monopolies and received multiple international certifications, addressing the industry pain point of non-degradable petroleum-based materials [4]. Group 3: Market Potential - With ongoing breakthroughs in synthetic biology technology and decreasing production costs, PHA production capacity is expected to increase rapidly, potentially reaching nearly 1 million tons globally by 2029, accounting for about 25% of the total capacity of biodegradable plastics [4]. - The upcoming "5th China Synthetic Biology and Bio-Manufacturing Conference" will be held in Hangzhou, featuring a session on bio-based chemicals and materials, inviting experts and industry practitioners for discussions [4].